Valuation
- Market cap
- 1,068,466,000
- Revenue TTM
- $0
- Net income TTM
- $-695,981,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 773,200
- Avg volume
- 997,338
- Day's range
- $18.09 – $18.99
- Shares out
- 59,162,000
- Stochastic %K
- 19%
- Beta
- 1.78
- Analysts
- Strong Sell
- Price target
- $37.43
Company profile
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for t...
Show more
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 655 6580
- Website
- https://www.vorbio.com
- Address
- 500 Boylston Street, Suite 1350, Boston, United States
Latest news
No headlines yet.
